In Q1 2023, Eventide Asset Management held 103 positions worth $3.7B. They initiated 103 new positions. Their largest holding was PANW ($171.6M).
Frequently asked questions
What stocks did Eventide Asset Management own in Q1 2023?
Eventide Asset Management held 103 biotech stocks in their 13F portfolio in Q1 2023. Their top positions include PANW, DOCS, TT, ROP, EXAS. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Eventide Asset Management's portfolio worth in Q1 2023?
Eventide Asset Management's tracked biotech portfolio was worth $3.7B across 103 positions, with total assets under management of approximately $6B. Portfolio values are based on 13F filings with the SEC.
What did Eventide Asset Management buy in Q1 2023?
Eventide Asset Management initiated 103 new positions in Q1 2023, including PANW, DOCS, TT, ROP, EXAS and 98 more. They also increased 0 existing positions.
What did Eventide Asset Management sell in Q1 2023?
Eventide Asset Management did not fully exit any positions in Q1 2023.
Is Eventide Asset Management a biotech fund?
Values-based investment firm with significant biotech allocation. Kuruvilla—a physician, engineer, and PhD—leads a team that evaluates companies on both financial merit and alignment with ethical principles. Known for holding high-conviction biotech positions alongside broader healthcare and technology investments.
Want AI analysis, insider signals, and catalyst overlays for Eventide Asset Management?
View latest Eventide Asset Management portfolio →